Vendor Intelligence Report: P3 Labz

Published 13 Jun 2026. 22-page investigative report on who is behind P3 Labz: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, P3 Labz records 5 pass / 1 fail, an overall pass rate of 83%. All six were public-submitted and all were Tirzepatide, so the useful signal is narrow. Later samples look directionally strong for identity and purity, but the record also shows real vial-fill spread, including one materially overfilled 30mg claim and another underfilled 30mg claim. For a Tirzepatide buyer, this is not a repeated-identity-failure profile; it is a batch-verification and dose-planning profile.

The channel behind those vials is less clean than the chemistry. P3 Labz sells through a WhatsApp number, while the P3-branded domain has no substantive public history and no certificate-transparency footprint in the captured record. The corporate trail resolves instead to a young California vehicle, Biotech Labz Supply Inc., with a single named officer/director and a separate public-facing sourcing persona marketing China manufacturer relationships.

The supply-chain trail is the report’s strongest hook: one P3 Labz Tirzepatide batch identifier also appears under Uther’s label, showing shared upstream wholesale supply rather than original manufacturing by P3 Labz. ZE-prefix lots point toward a plausible Chinese supplier family, but the report treats that attribution as a lead, not a proven manufacturer. No sterility, endotoxin, or microbial testing surfaced.

Directional read: P3 Labz is potentially reasonable only for Tirzepatide, and only when the exact batch can be checked against independent testing. There is no Finnrick basis here for assuming other P3 Labz peptides perform similarly, and stricter grading makes the fill-accuracy problem harder to ignore.

Inside the full report:

  • Complete six-test Tirzepatide history with certificates, batch IDs, quantity deviations, and methodology-divergence analysis
  • California Secretary of State filing analysis for Biotech Labz Supply Inc. and the P3 Labz brand relationship
  • Domain and storefront authentication trail covering p3labz.com, biotechlabzsupply.com, Wayback, and certificate-transparency searches
  • Shared-batch comparison between P3 Labz and Uther, plus the ZE-prefix Chinese supplier-attribution lead
  • WhatsApp number reconciliation, Alabama/Delaware registry dead ends, and channel-control risk assessment
  • Promotion and reputation sweep across X, coupon sites, web Reddit, Instagram/TikTok, Trustpilot, and community-review surfaces

Risk assessment

  • Tirzepatide fill-accuracy risk — high: P3 Labz’s only tested product is Tirzepatide; certificates document major fill variation, including 37mg on a 30mg claim and 26.6mg on a 30mg claim.
  • Sterility-verification gap — high: No sterility, endotoxin, or microbial testing surfaced for injectable Tirzepatide; chemistry COAs are not sterility assurance.
  • Supply-chain traceability and repackager risk — high: Batch ZE60-1123 appears in both P3 Labz and Uther records, showing shared wholesale supply while the true manufacturer is not disclosed to buyers.
  • Channel-authenticity and corporate-transparency concern — medium: P3 Labz has no standalone entity found, p3labz.com is blank/no-cert in the supplied searches, and the Alabama WhatsApp number does not reconcile cleanly with the California corporation.
  • Vendor testing-initiative gap — medium: All six Finnrick tests were public-submitted; no vendor-initiated Finnrick submissions were found despite marketing language around third-party testing.